Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies
Sign Up to like & getrecommendations! Published in 2020 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2020.1797482
Abstract: ABSTRACT Introduction Development of the BTK inhibitor ibrutinib has changed the landscape of CLL treatment producing durable responses with minimal to no myelosuppression. Although remissions are durable, relapses remain a challenge. Areas covered Data from… read more here.
Keywords: resistance chronic; treatment; mechanisms ibrutinib; resistance ... See more keywords